Icatibant for the treatment of hereditary angioedema

Bibliography

• Craig T, Riedl M, Dykewicz MS, et al. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 2009;102:366-72
   PubMed Web of Science ®Google Scholar
• Cicardi M, Bergamaschini L, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982;284:2-9
   PubMed Web of Science ®Google Scholar
• Bork K, Hardt J, Schicketanz K-H, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 2003;163:1229-35
   PubMed Web of Science ®Google Scholar
• Wilson DA, Bork K, Shea EP, et al. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104:314-20
   PubMed Web of Science ®Google Scholar
• Maurer M, Aberer W, Bouillet L, et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 2013;8:e53773
   PubMed Web of Science ®Google Scholar
• Craig T, Aygören-Pürsün E, Bork K, et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 2012;5:182-99
   PubMedGoogle Scholar
• Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008;359:1027-36
   PubMed Web of Science ®Google Scholar
• Riedl M. Creating a comprehensive treatment plan for hereditary angioedema. Immunol Allergy Clin N Am 2013;33:471-85
   PubMed Web of Science ®Google Scholar
• Cicardi M, Bork K, Caballero T, et al. HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67:147-57
   PubMed Web of Science ®Google Scholar
• Bernstein J. On-demand therapy for hereditary angioedema. Immunol Allergy Clin N Am 2013;33:487-94
   PubMedGoogle Scholar
• Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998;351:1693-7
   PubMed Web of Science ®Google Scholar
• Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy 2007;62:842-56
   PubMed Web of Science ®Google Scholar
• Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol 1994;38:317-21
   PubMed Web of Science ®Google Scholar
• Cruden N, Newby D. Therapeutic potential of icatibant (HOE-140, JE-049). Expert Opin Pharmacother 2008;9:2383-90
   PubMed Web of Science ®Google Scholar
• Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991;102:769-73
   PubMed Web of Science ®Google Scholar
• Wirth K, Hock F, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991;102:774-7
   PubMed Web of Science ®Google Scholar
• Han E, MacFarlane R, Mulligan A, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;109:1057-63
   PubMed Web of Science ®Google Scholar
• Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007;119:1497-503
   PubMed Web of Science ®Google Scholar
• Product information: firazyr solution for subcutaneous injection. Shire Orphan Therapies, Inc., Lexington, MA; 2011
   Google Scholar
• Bouillet L. Icatibant in hereditary angioedema: news and challenges. Expert Rev Clin Immunol 2011;7:267-72
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency CHMP assessment report for Firazyr®. 2008. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/000899/WC500022970.pdf [Last accessed 5 April 2013]
   Google Scholar
• Deeks ED. Icatibant. Drugs 2010;70(1):73-81
   PubMed Web of Science ®Google Scholar
• Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532-41
   PubMed Web of Science ®Google Scholar
• Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011;107:529-37
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Advisory Committee Meeting Briefing Package. Firazyr® (icatibant). Available from: Materials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM260022.pdf [Last accessed 25 January 2012]
   Google Scholar
• Schmidt P, Hirschl M, Trautinger F. Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant. J Am Acad Dermatol 2010;63:913-14
   PubMedGoogle Scholar
• Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, et al. On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy Asthma Clin Immunol 2010;6:21
   PubMedGoogle Scholar
• Longhurst H. Management of acute attacks of hereditary angioedema: potential role of icatibant. Vasc Health Risk Manag 2010;6:795-802
   PubMedGoogle Scholar
• Bossi F, Fischetti F, Regoli D, et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 2009;124(6):1303-10
   PubMed Web of Science ®Google Scholar
• Aberer W, Maurer M, Reshef A, et al. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy 2014;69(305):14
   Google Scholar
• Lang D, Aberer W, Bernsteinet J, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol 2012;109:395-402
   PubMed Web of Science ®Google Scholar
• Blankart CR, Stargardt T, Schreyogg J. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukemia. Pharmacoeconomics 2011;29:63-82
   PubMed Web of Science ®Google Scholar
• Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014;69:602-16
   PubMed Web of Science ®Google Scholar
• Bouillet L. Hereditary angioedema in women. Allergy Asthma Clin Immunol 2010;6:17
   PubMedGoogle Scholar
• Guichon C, Floccard B, Coppere B, et al. One hypovolaemic shock, two kinin pathway abnormalities. Intensive Care Med 2011;37:1227-8
   PubMedGoogle Scholar
• Colas C, Montoiro R, Fraj J, et al. Nonhistaminergic idiopathic angioedema: clinical response to icatibant. J Investig Allergol Clin Immunol 2012;22:520-1
   PubMedGoogle Scholar
• Del Corso I, Puxeddu I, Sardano E, et al. Treatment of idiopathic nonhistaminergic angioedema with bradykinin B2 receptor antagonist icatibant. Ann Allergy Asthma Immunol 2012;108:460-1
   PubMedGoogle Scholar
• Montinaro V, Loizzo G, Zito A, et al. Successful treatment of a facial attack of angioedema with icatibant in a patient with idiopathic angioedema. Am J Emerg Med 2013;31:1295
   PubMedGoogle Scholar
• Bright P, Dempster J, Longhurst H. Successful treatment of acquired C1 inhibitor deficiency with icatibant. Clin Exp Dermatol 2010;35:553-5
   PubMedGoogle Scholar
• Weller K, Magerl M, Maurer M. Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J Eur Acad Dermatol Venereol 2011;25:119-20
   PubMedGoogle Scholar
• Bygum A, Broesby-Olsen S. Rapid resolution of erythema marginatum after icatibant in acquired angioedema. Acta DermVenereol 2011;91:185-6
   PubMedGoogle Scholar
• Zanichelli A, Bova M, Coerezza A, et al. Icatibant treatment for acquired C1-inhibitor deficiency:a real-world observational study. Allergy 2012;67:1074-7
   PubMedGoogle Scholar
• Gallitelli M, Alzetta M. Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors. Am J Emerg Med 2012;30:1664
   PubMedGoogle Scholar
• Bouillet L, Boccon-Gibod I, Ponard D, et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol 2009;103:448
   PubMed Web of Science ®Google Scholar
• Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010;56:278-82
   PubMed Web of Science ®Google Scholar
• Vanderbilt University. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. US National Library of Medicine, Bethesda, MD, USA. Available from: http://clinicaltrials.gov/ct2/show/NCT01574248
   Google Scholar